KTE-X19 produces highest response rate in MCL subgroupDecember 14, 2019Mantle Cell LymphomaB Cell Lymphoma
Orelabrutinib could be ‘preferred’ BTK inhibitor for MCLDecember 12, 2019Mantle Cell LymphomaB Cell Lymphoma
Acalabrutinib may outperform other targeted therapies in MCLDecember 4, 2019Mantle Cell LymphomaB Cell Lymphoma
FDA approves Brukinsa for relapsed, refractory MCLNovember 15, 2019Mantle Cell LymphomaB Cell Lymphoma
Survival ‘excellent’ after rituximab-bendamustine induction in transplant-eligible MCLNovember 6, 2019Mantle Cell Lymphoma
ASCO to award $50,000 young investigator grant to study MCLOctober 23, 2019Mantle Cell LymphomaNon-Hodgkin Lymphoma
Follow-up shows favorable results with acalabrutinib in MCLOctober 8, 2019Mantle Cell LymphomaB Cell Lymphoma
Staging PET/CT better defines extent of mantle cell lymphomaSeptember 19, 2019Mantle Cell LymphomaB Cell Lymphoma
Rituximab, bendamustine look better than chemo alone in MCLSeptember 7, 2019Mantle Cell LymphomaB Cell Lymphoma
Ibrutinib-rituximab induction yields ‘unprecedented’ responses in MCLAugust 27, 2019Mantle Cell LymphomaB Cell Lymphoma
Ibrutinib/rituximab effective, safe as frontline treatment for older patients with MCLAugust 12, 2019Mantle Cell LymphomaB Cell Lymphoma
Low-dose radiation therapy looks effective in hard-to-treat MCLAugust 7, 2019Mantle Cell LymphomaB Cell Lymphoma
Flavopiridol elicits poor response in mantle cell lymphoma, DLBCLJuly 18, 2019Mantle Cell LymphomaB Cell LymphomaDLBCL
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomasJune 21, 2019Aggressive LymphomasB Cell LymphomaMantle Cell Lymphoma
